No Evidence of Reactivation of Hepatitis B Virus among Patients Treated with Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection

Mark S. Sulkowski, Wan Long Chuang, Jia Horng Kao, Jenny C. Yang, Bing Gao, Diana M. Brainard, Kwang Hyub Han, Edward Gane

Research output: Contribution to journalArticle

Abstract

Postmarketing cases of hepatitis B virus (HBV) reactivation during hepatitis C treatment have been reported. We analyzed serum samples from patients in a clinical trial of ledipasvir-sofosbuvir in Taiwan and Korea. Of the 173 patients enrolled, 103 (60%) had been previously infected with HBV. None showed evidence of HBV reactivation.

Original languageEnglish (US)
Pages (from-to)1202-1204
Number of pages3
JournalClinical Infectious Diseases
Volume63
Issue number9
DOIs
StatePublished - Nov 1 2016

Keywords

  • ALT flare
  • HBV reactivation
  • HCV/HBV coinfection

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'No Evidence of Reactivation of Hepatitis B Virus among Patients Treated with Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection'. Together they form a unique fingerprint.

  • Cite this